3724-16-1

Usage

Uses

Used in Pharmaceutical Research and Development:
2-(PYRIDIN-3-YL)ACETAMIDE is used as a chemical intermediate for the synthesis of various pharmaceutical compounds, leveraging its unique structure to target specific receptors in biological systems. Its potential medicinal properties are being investigated for the development of drugs to treat neurological disorders and cancer.
Used in Organic Synthesis:
As a building block in organic synthesis, 2-(PYRIDIN-3-YL)ACETAMIDE is utilized in the creation of complex organic molecules. Its presence in chemical databases facilitates its use by researchers and chemists for reference and further exploration in the synthesis of novel compounds.
Used in Chemical Databases:
2-(PYRIDIN-3-YL)ACETAMIDE is featured in various chemical databases, serving as a reference for researchers and scientists. It provides valuable information for those studying its properties, potential applications, and its role in the synthesis of other compounds.

InChI:InChI=1/C7H8N2O/c8-7(10)4-6-2-1-3-9-5-6/h1-3,5H,4H2,(H2,8,10)

Upstream product

• 350-03-8 methyl-3-pyridylketone 
• 39998-25-9 methyl pyridine-3-acetate 
• 39931-77-6 pyridin-3-yl-acetic acid ethyl ester 
• 501-81-5 pyridyl-3-yl-acetic acid 
• 6443-85-2 3-pyridinylacetonitrile 

Downstream Products

• 6443-85-2 3-pyridinylacetonitrile 
• 100-54-9 pyridine-3-carbonitrile 
• 6302-03-0 1-(pyridin-3-yl)-2-propanone 
• 71271-61-9 (+/-)-1-(3-pyridyl)propan-2-amine 
• 34672-31-6 [3]pyridyl-acetone oxime 

Relevant academic research and scientific papers

Hydration of Aliphatic Nitriles Catalyzed by an Osmium Polyhydride: Evidence for an Alternative Mechanism

The hexahydride OsH6(PiPr3)2 competently catalyzes the hydration of aliphatic nitriles to amides. The main metal species under the catalytic conditions are the trihydride osmium(IV) amidate derivatives OsH3{κ2-N,O-[HNC(O)R]}(PiPr3)2, which have been isolated and fully characterized for R = iPr and tBu. The rate of hydration is proportional to the concentrations of the catalyst precursor, nitrile, and water. When these experimental findings and density functional theory calculations are combined, the mechanism of catalysis has been established. Complexes OsH3{κ2-N,O-[HNC(O)R]}(PiPr3)2 dissociate the carbonyl group of the chelate to afford κ1-N-amidate derivatives, which coordinate the nitrile. The subsequent attack of an external water molecule to both the C(sp) atom of the nitrile and the N atom of the amidate affords the amide and regenerates the κ1-N-amidate catalysts. The attack is concerted and takes place through a cyclic six-membered transition state, which involves Cnitrile···O-H···Namidate interactions. Before the attack, the free carbonyl group of the κ1-N-amidate ligand fixes the water molecule in the vicinity of the C(sp) atom of the nitrile.

Manganese-Pincer-Catalyzed Nitrile Hydration, α-Deuteration, and α-Deuterated Amide Formation via Metal Ligand Cooperation

A simple and efficient system for the hydration and α-deuteration of nitriles to form amides, α-deuterated nitriles, and α-deuterated amides catalyzed by a single pincer complex of the earth-abundant manganese capable of metal-ligand cooperation is reported. The reaction is selective and tolerates a wide range of functional groups, giving the corresponding amides in moderate to good yields. Changing the solvent from tert-butanol to toluene and using D2O results in formation of α-deuterated nitriles in high selectivity. Moreover, α-deuterated amides can be obtained in one step directly from nitriles and D2O in THF. Preliminary mechanistic studies suggest the transformations contributing toward activation of the nitriles via a metal-ligand cooperative pathway, generating the manganese ketimido and enamido pincer complexes as the key intermediates for further transformations.

Corresponding amine nitrile and method of manufacturing thereof

The invention relates to a manufacturing method of nitrile. Compared with the prior art, the manufacturing method has the characteristics of significantly reduced using amount of an ammonia source, low environmental pressure, low energy consumption, low production cost, high purity and yield of a nitrile product and the like, and nitrile with a more complex structure can be obtained. The invention also relates to a method for manufacturing corresponding amine from nitrile.

Aryl-indolyl maleimides as inhibitors of CaMKIIδ. Part 1: SAR of the aryl region

A family of aryl-substituted maleimides was prepared and studied for their activity against calmodulin dependant kinase. Inhibitory activities against the enzyme ranged from 34 nM to >20 μM and were dependant upon both the nature of the aryl group and the hydrogen bond donating potential of the maleimide ring. Key interactions with the kinase ATP site and hinge region were found to be consistent with homology modeling predictions.

Cyanoamidine P2X7 antagonists for the treatment of pain

Novel cyanoamidines compounds of formula (I) and (II) and their derivatives wherein R1-R12 are as defined in the specification act as antagonists of the P2X7 receptor. These compounds are particularly useful in the treatment of pain, inflammation and neurodegeneration states.

Mild oxidative one-carbon homologation of aldehyde to amide

One-carbon homologation of aldehyde into amide is realized in one-pot by its reaction with potassium α-p-methoxyphenyl-α-isocyano acetic acid (1c) and hydrochloride salt of dimethylamine (3a) in toluene at room temperature followed by acidic workup. In this multicomponent reaction, 1c served as donor of the CONH2 function to aldehyde, while the dimethylamine acted as a shuttle molecule to initiate/terminate the sequence and to mediate the internal redox process of one of the three-component adducts. Ready accessibility, nominal cost of the reagents, and mild conditions are attractive features of the present method. Copyright

3,4-DISUBSTITUTED MALEIMIDES FOR USE AS VASCULAR DAMAGING AGENTS

This invention relates to novel compounds of Formula (I) for use as vascular damaging agents: Formula (I) wherein Rl, R7, R8, R9, ARI, AR2, AR3, p, q and r are as described in the specification. The invention also relates to methods for preparing compounds of Formula (I), to their use as medicaments (including methods for the treatment of angiogenesis or disease states associated with angiogenesis) and to pharmaceutical compositions containing compounds of Formula (I).

11a-Methano-TXA compounds

The present invention provides novel 11a-methano-TXA compounds and intermediates and processs for their preparation. Further provided are methods for using these novel TXA analogs as inhibitors of thromboxane synthetase, rendering these analogs useful for a variety of pharmacological purposes. These pharmacological uses include anti-inflammatory, anti-thromobitc, and anti-asthma indications.